[Recommended guideline for the use of medical therapy in pulmonary hypertension].
Pulmonary arterial hypertension (PAH), previously known as primary pulmonary hypertension, is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. Recently dramatic advance in medical therapy including prostanoids, endothelin-receptor antagonists, phosphodiesterase 5 inhibitors, has occurred, and American College of Chest Physicians(ACCP) Evidence-Based Clinical Practice Guidelines have been proposed, followed by several guidelines for treatment of pulmonary hypertension in our country. Additionally several reports have provided utility of combination therapy. This article summarizes recent medical therapy for PAH including updated ACCP guidelines in 2007, further advance, and recommended therapeutic approach for PAH, available in our country.
Tanabe
Nobuhiro
N
Department of Respirology, Graduate School of Medicine, Chiba University.
D017408:Guidelines as Topic; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*